Company Description
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components.
This segment also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support.
This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.
The company serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors.
West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.
| Country | United States |
| Founded | 1923 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 10,600 |
| CEO | Eric M. Green |
Contact Details
Address: 530 Herman O. West Drive Exton, Pennsylvania 19341 United States | |
| Phone | (610) 594-2900 |
| Website | westpharma.com |
Stock Details
| Ticker Symbol | WST |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000105770 |
| CUSIP Number | 955306105 |
| ISIN Number | US9553061055 |
| Employer ID | 23-1210010 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Eric M. Green | Non-Independent Chair of the Board, President and Chief Executive Officer |
| Bernard J. Birkett | Senior Vice President and Chief Financial and Operations Officer |
| Silji Abraham | Senior Vice President and Chief Technology Officer |
| Kimberly Banks MacKay | Senior Vice President, General Counsel and Company Secretary |
| Cindy Reiss-Clark | Senior Vice President and Chief Commercial Officer |
| Chad R. Winters | Vice President, Chief Accounting Officer and Corporate Controller |
| Dr. Quintin J. Lai C.F.A., Ph.D. | Vice President of Strategy and Investor Relations |
| Michele Polinsky | Vice President of Global Communications |
| Rudy Poussot | Senior Vice President of Strategy and Corporate Development |
| Annette F. Favorite | Chief Human Resources Officer and Senior Vice President |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 25, 2024 | 10-Q | Quarterly Report |
| Apr 25, 2024 | 8-K | Current Report |
| Mar 19, 2024 | PX14A6G | Notice of exempt solicitation submitted by non-management |
| Mar 13, 2024 | ARS | Filing |
| Mar 13, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 13, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 1, 2024 | PRE 14A | Other preliminary proxy statements |
| Feb 27, 2024 | 144 | Filing |
| Feb 20, 2024 | 10-K | Annual Report |
| Feb 15, 2024 | 8-K | Current Report |